Detecting Therapeutic Targets in Pediatric Rhabdomyosarcoma with 3D Genomics

Value of the Information & Strength of the Argument

The webinar provides valuable information on the application of 3D genomics in cancer research, particularly for fusion detection and regulatory element analysis. The argumentation is solid, supported by published studies (e.g., Kloetgen et al., 2020 in Nature Genetics) and original data from the collaboration. The speakers clearly explain the technology and its advantages over traditional methods, such as the ability to detect structural variants without needing reads spanning the breakpoint. The case study of a pediatric glioma patient where a novel PD-L1 fusion was identified and led to treatment change is compelling. However, the presentation is partly promotional for Arima’s product, which may introduce bias, but the scientific content remains rigorous.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high: the webinar references peer-reviewed studies and presents original data with appropriate methodology. The sources cited include the Cancer Gene Census, MSKCC’s actionable cancer gene list, and specific publications (e.g., Kloetgen et al., 2020). The title accurately reflects the content. The presentation includes a clear disclosure of no conflicts of interest from the second speaker. The commercial nature of the first part is transparent, but it does not undermine the scientific validity. The webinar is well-structured and provides sufficient detail for a technical audience.

The title accurately reflects the content: the webinar focuses on using 3D genomics to detect therapeutic targets in pediatric rhabdomyosarcoma, with a detailed case study.

8/10

The webinar presents a commercial product (Arima Oncology Panel) but includes peer-reviewed study examples and original data from a collaboration with Children's Mercy Hospital. The speaker discloses no conflicts of interest. The methodology is based on established Hi-C technology, and the results are presented with appropriate caution.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to Arima Genomics and 3D genomics technology platform.
• 10:00Explanation of 3D genome features: chromosome territories, compartments, TADs, and loops.
• 20:00Case study: detection of a novel PD-L1 structural variant in a pediatric glioma patient.
• 30:00Introduction of the Arima Oncology Panel: 1404 genes, features, and early access program.
• 40:00Dr. Atif Ahmed presents background on rhabdomyosarcoma and the need for new molecular methods.
• 50:00Results of the Hi-C study on rhabdomyosarcoma samples: detection of PAX3/PAX7-FOXO1 fusions.

• Arima Genomics website — Mentioned as the company's website for product information and early access registration.
• Kloetgen et al., 2020, Nature Genetics — Study on 3D genome organization in T-ALL, cited as an example of 3D genomics informing therapy.
• Cancer Gene Census — Referenced as a source for cancer gene targets included in the panel.
• MSKCC actionable cancer gene list — Referenced as a source for actionable cancer targets.

• Kloetgen et al., 2020, Nature Genetics — Supports the role of 3D genome organization in oncogene regulation.
• Arima Genomics publications — Company website listing peer-reviewed publications using their technology.